Source: Rush University Medical Center
Date: March 27, 2007
Summary:
Heart attack patients who received an new intravenous adult stem cell therapy, Provacel™, experienced a lower number of adverse events, such as cardiac arrhythmias, and had significant improvements in heart, lung and global function compared to those who received a placebo, according to six-month Phase I study data presented at the American College of Cardiology’s Innovation in Intervention: i2Summit in New Orleans.
